Market Overview

UPDATE: Sterne Agee Upgrades athenahealth to Neutral; Overhang Removed

Share:
Related ATHN
Greenlight's Q4 Letter Reveals Another Tough Quarter For David Einhorn
Analyst: When Americans Sneeze, Teladoc And Athenahealth Profit
Greenlight Capital's (David Einhorn) Q4 2017 Letter (Seeking Alpha)

Sterne Agee raised its rating on athenahealth (NASDAQ: ATHN) from Underperform to Neutral and increased its price target from $48.50 to $72.

Sterne Agee noted, "Contrary to our fears toward a significant air pocket in revenues created by the loss of a material channel partnership with PSS World Medical (PSSI, $28.48, NR), we now believe this relationship will continue. In hindsight, our industry checks had caused our view towards the ATHNPSSI partnership to become black and white, whereby we thought the partnership would end upon the consummation of PSSI's marriage with McKesson (MCK, $95.30, NR). We now believe McKesson will allow the PSS sales force the option to sell athena's solutions or MCK's solutions"

athenahealth closed at $73.89 on Friday.

Latest Ratings for ATHN

DateFirmActionFromTo
Dec 2017Deutsche BankInitiates Coverage OnHold
Oct 2017Leerink SwannMaintainsMarket Perform
Oct 2017BairdMaintainsOutperform

View More Analyst Ratings for ATHN
View the Latest Analyst Ratings

Posted-In: Sterne AgeeAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ATHN)

View Comments and Join the Discussion!